SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention ahead of the anticipated Phase 3 REGAL topline results for its GPS AML therapy, following the trials 80th-event milestone; the release timing and outcome remain unconfirmed. Many traders are betting on strong survival data, while skeptics point to the sharp share-price decline and warn that the results could disappoint; SLS009s AML data is a secondary topic.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Fireflys multiyear engine-supply, technology-licensing, and engineering deal with AST SpaceMobile is driving attention, with traders viewing it as validation of Fireflys propulsion business and a boost to its backlog and funding outlook. The reaction is largely bullish, though some question the deals cash-and-stock structure, possible dilution, and how quickly the contract translates into revenue.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris strong Q3 results, faster Recorlev growth, and raised revenue outlookincluding a higher long-term targetare driving a sharp reassessment of its growth prospects. Traders are broadly celebrating the results and analyst upgrades, while takeover speculation is circulating but remains unconfirmed.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

OKLO rebounded sharply around its Q3 results and an agreement reserving U.S. Forged Rings capacity for future reactor components. Traders are split on whether the manufacturing milestone and cash position support the nuclear-growth story or whether pre-revenue status, dilution concerns, insider selling and a long path to deployment weigh more heavily.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

X-Energys extension of its Fluor partnership on a Washington small modular reactor project is drawing attention amid a sharp share rebound. Traders are split between treating the move and broader nuclear-power demand as signs of long-term potential and viewing it as a speculative bounce after a prolonged selloff, with commercial execution still years away.

Aurora Cannabis, Inc. engages in the production, distribution, and sale of cannabis and cannabis-derivative products. It operates through the following business segments: Cannabis and Plant Propagation. The company was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Edmonton, Canada.

Aurora Cannabis Inc

Auroras agreed acquisition by Organigram is driving attention, with traders discussing the deals terms and whether Curaleaf may return with a higher competing offer. Some holders see the agreement as undervaluing Aurora and favor waiting for a better bid, while others support taking the deal; completion remains subject to approvals.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

Attention centers on lorundrostats upcoming FDA decision and additional clinical data, with traders debating the drugs prospects amid a steep share-price slide. Bulls point to prior positive trial results and the regulatory catalyst, while skeptics question commercialization against AstraZenecas competing Baxfendy and cite its slow launch and limited coverage.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Anticipation of Netlists Q3 report and conference call dominates, with traders hoping for strong results and updates on a possible SK hynix licensing renewal or Nasdaq relisting; those updates remain speculative. Optimism is tempered by volatile memory and AI shares, while the companys Kingston-related ITC action adds to discussion of its patent-licensing strategy.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

A Foxconn Tech Day display that traders identify as featuring POET technology, alongside the appointment of a new CFO, has renewed interest in the companys optical-engine opportunity for AI data centers. Bulls see the display as validation and hope for orders or production updates, while skeptics note it is not proof of new purchase orders or scaled shipments.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

Gold miners are rebounding alongside firmer gold, prompting talk of a technical turn and short-covering. Traders remain divided on whether the bounce can last, with some warning that higher yields and rate concerns could keep pressure on the sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
